The Avience Biomedicals IPO, an NSE SME issue, saw massive investor response, subscribing over 350 times by its final day. The diagnostics firm raised Rs 30.24 crore to fund a new manufacturing facility in Uttar Pradesh. With the bidding process now complete, the company is set to list on the NSE Emerge platform on June 25, 2026.
What Happened
Avience Biomedicals Limited concluded its initial public offering (IPO) on June 22, 2026, witnessing strong investor interest. The SME issue, which opened on June 18, was subscribed over 350 times by the final day of bidding. The company offered 14.53 lakh shares in a price band of Rs 196 to Rs 208 per share to raise Rs 30.24 crore. Retail, non-institutional, and institutional investors all participated heavily in the share sale.
Business And Expansion Strategy
The company operates in the medical diagnostics sector, manufacturing in-vitro diagnostic (IVD) products, rapid test kits, and medical devices. It supplies products like biochemical analyzers and reagents to pathology laboratories, hospitals, and research centers. A significant portion of the IPO proceeds—approximately Rs 15.96 crore—is earmarked for setting up a new manufacturing unit at the Medical Device Park in the Yamuna Expressway Industrial Development Authority (YEIDA) region, Gautam Buddha Nagar, Uttar Pradesh. The remaining funds are allocated to working capital and general corporate needs.
Financial And Operational Context
Avience Biomedicals has reported growth in recent years. For the financial year 2025, the company posted a revenue of Rs 45.97 crore with a net profit of Rs 7.23 crore. The firm's product portfolio covers a range of testing needs, including kits for diseases like dengue, malaria, and HIV, as well as biochemistry equipment. By expanding its manufacturing footprint, the company aims to scale its operations to meet rising domestic demand for diagnostic testing and medical equipment.
SME IPO Risks And Considerations
While the high oversubscription reflects strong market sentiment, investors in SME IPOs should be mindful of specific risks. SME stocks often face lower liquidity compared to mainboard stocks, which can lead to higher price volatility and wider gaps between buy and sell orders. Furthermore, the company’s business model depends on government healthcare policies, regulatory standards for medical devices, and the ability to maintain consistent product quality. The success of the planned manufacturing expansion will also depend on timely execution and the ability to manage operational costs effectively.
What Investors Should Track Next
The next key development for applicants is the share allotment, which is expected on June 23, 2026, followed by the listing on the NSE Emerge platform on June 25, 2026. Investors who were allotted shares will watch for the listing day performance and subsequent liquidity. For the long term, monitorables include the construction progress of the new Uttar Pradesh manufacturing facility, the company’s ability to maintain profit margins amid sector competition, and any updates regarding regulatory compliance for its medical device portfolio.